
On Monday, Replimune Group Inc. (NASDAQ:REPL) is reeling after the FDA unexpectedly rejected its skin cancer treatment, triggering a stock plunge and a wave of investor outrage.
Shares fell sharply Monday on heavy volume, capping a month-long slide of nearly 43%.